Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a diversified line of healthcare products including: drugs, nutritional products, diabetes monitoring devices and diagnostics.
All pharmaceutical companies face the inevitable patent expirations and the ensuing generic competition. However, ABT’s product pipeline includes potential significant launches in the medical device and pharmaceutical areas. With its strong financials and excellent management team, ABT is in a position to continue its growth and to generate strong returns. I will continue to add to my position while it is trading below my buy price of $61.24 and as my allocation allows.
Source: Dividends Value
Related Articles:
Dividend Growth Stocks News
Stock Analysis: Abbott Laboratories (ABT)
Posted by D4L | Thursday, May 06, 2010 | ArticleLinks | 0 comments »________________________________________________________________
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment
Post a Comment
Note: Only a member of this blog may post a comment.